Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERAATH: Bosentan and Ambrisentan in Athletes
NCT01352065Phase 3Completed
- Start
- Jan 2011
- Primary completion
- Dec 2012
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of bosentan, ambrisentan in pulmonary arterial hypertension (PAH). Started Jan 2011; status: completed.
02
Drugs
bosentanambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01352065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352065.